Susan L Cohn

List of Publications by Year
in descending order

192 papers	17,538 citations	19657 61 h-index	15266 126 g-index
194 all docs	194 docs citations	194 times ranked	12045 citing authors

#	Article	IF	Citations
1	The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for ¹³¹I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. , 2022, 39, 304-316.		3
2	Rethinking highâ€risk neuroblastoma treatment. Pediatric Blood and Cancer, 2022, 69, e29730.	1.5	1
3	Efficacy of postâ€induction therapy for highâ€risk neuroblastoma patients with endâ€induction residual disease. Cancer, 2022, 128, 2967-2977.	4.1	5
4	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 4107-4118.	1.6	11
5	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with highâ€risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 2021, 68, e28794.	1.5	29
6	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research, 2021, 27, 2179-2189.	7.0	95
7	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	1.6	174
8	Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. , 2021, 9, e002417.		21
9	Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Network Open, 2021, 4, e2116248.	5.9	5
10	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of Clinical Oncology, 2021, 39, 3506-3514.	1.6	38
11	Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO Clinical Cancer Informatics, 2021, 5, 1034-1043.	2.1	18
12	Stage 4S Neuroblastoma. American Journal of Surgical Pathology, 2021, 45, 1075-1081.	3.7	10
13	Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clinical Cancer Informatics, 2021, 5, 1181-1188.	2.1	3
14	5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clinical Cancer Research, 2020, 26, 1309-1317.	7.0	22
15	Unrealistic parental expectations for cure in poorâ€prognosis childhood cancer. Cancer, 2020, 126, 416-424.	4.1	34
16	Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clinical Cancer Informatics, 2020, 4, 895-905.	2.1	36
17	Association between endâ€induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in highâ€risk neuroblastoma patients. Pediatric Blood and Cancer, 2020, 67, e28390.	1.5	6
18	Reply to K. Beiske et al. Journal of Clinical Oncology, 2020, 38, 3720-3721.	1.6	0

#	Article	IF	Citations
19	Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient. Pediatric Blood and Cancer, 2020, 67, e28218.	1.5	1
20	The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2020, 67, e28359.	1.5	28
21	Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. Journal of Pain and Symptom Management, 2020, 60, 782-789.	1.2	27
22	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. Journal of Clinical Oncology, 2020, 38, 1906-1918.	1.6	41
23	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Childrenâ€™s Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 3243-3255.	1.6	61
24	Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Molecular Cancer Therapeutics, 2019, 18, 507-516.	4.1	22
25	5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. JCO Precision Oncology, 2019, 3, 1-12.	3.0	14
26	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Childrenâ€™s Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 115-124.	1.6	45
27	Role of the extent of prophylactic regional lymph node radiotherapy on survival in highâ€risk neuroblastoma: A report from the COG A3973 study. Pediatric Blood and Cancer, 2019, 66, e27736.	1.5	8
28	The challenge of defining â€œultraâ€highâ€riskâ€•neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27556.	1.5	43
29	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clinical Cancer Research, 2018, 24, 189-196.	7.0	45
30	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. The Lancet Child and Adolescent Health, 2018, 2, 25-34.	5.6	38
31	Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. Biology of Blood and Marrow Transplantation, 2018, 24, 452-459.	2.0	10
32	Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clinical Cancer Informatics, 2018, 2, 1-15.	2.1	20
33	Computerâ€assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatric Blood and Cancer, 2018, 65, e27417.	1.5	4
34	Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clinical Cancer Research, 2018, 24, 6142-6149.	7.0	55
35	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the childrenâ€™s oncology group. Oncotarget, 2018, 9, 6416-6432.	1.8	31
36	The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. Journal of Pediatric Oncology Nursing, 2017, 34, 160-172.	1.5	2

#	Article	IF	Citations
37	Emerging and investigational therapies for neuroblastoma. Expert Opinion on Orphan Drugs, 2017, 5, 355-368.	0.8	27
38	Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. European Journal of Cancer, 2017, 72, 177-185.	2.8	59
39	Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 553-557.	2.8	9
40	Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. Journal of the National Cancer Institute, 2017, 109, .	6.3	20
41	Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients. Pediatric Blood and Cancer, 2017, 64, e26226.	1.5	5
42	Data Commons to Support Pediatric Cancer Research. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 746-752.	3.8	25
43	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology, 2017, 35, 2580-2587.	1.6	219
44	Data Commons to Support Pediatric Cancer Research. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 746-752.	3.8	20
45	Genetic discoveries and treatment advances in neuroblastoma. Current Opinion in Pediatrics, 2016, 28, 19-25.	2.0	44
46	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalinâ€Fixed Paraffinâ€Embedded Tissue Samples and Are Associated With Recurrence. Pediatric Blood and Cancer, 2016, 63, 1019-1023.	1.5	13
47	A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatric Blood and Cancer, 2016, 63, 1349-1356.	1.5	66
48	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma:ÂA study from the International Neuroblastoma Risk Group database. European Journal of Cancer, 2016, 65, 1-10.	2.8	56
49	Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemotherapy and Pharmacology, 2016, 77, 405-412.	2.3	24
50	Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget, 2016, 7, 76816-76826.	1.8	33
51	Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids. Oncotarget, 2016, 7, 77696-77706.	1.8	14
52	Identification of differentALKmutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget, 2016, 7, 87301-87311.	1.8	20
53	A Selfless Act. Journal of Clinical Oncology, 2015, 33, 3834-3835.	1.6	2
54	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	3.0	128

#	Article	IF	Citations
55	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clinical Cancer Research, 2015, 21, 2715-2721.	7.0	62
56	Stem Cell Transplant-Associated Wernicke Encephalopathy in a Patient with High-Risk Neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 2232-2234.	1.5	6
57	Surveillance of Childhood Cancer Survivors: A Lifelong Affair. Journal of Clinical Oncology, 2015, 33, 3531-3532.	1.6	5
58	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of Clinical Oncology, 2015, 33, 3008-3017.	1.6	637
59	Second malignancies in patients with neuroblastoma: The effects of riskâ€based therapy. Pediatric Blood and Cancer, 2015, 62, 128-133.	1.5	51
60	Efavirenzâ€•but not nevirapineâ€based antiretroviral therapy decreases exposure to the levonorgestrel released from a subâ€dermal contraceptive implant. Journal of the International AIDS Society, 2014, 17, 19484.	3.0	23
61	Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group. Pediatric and Developmental Pathology, 2014, 17, 441-449.	1.0	35
62	Treatment of two cases with refractory, metastatic intermediateâ€risk neuroblastoma with isotretenoin alone or observation. Pediatric Blood and Cancer, 2014, 61, 1104-1106.	1.5	5
63	Time to disease progression in children with relapsed or refractory neuroblastoma treated with <scp>ABT</scp>â€751: A report from the Children's Oncology Group (ANBL0621). Pediatric Blood and Cancer, 2014, 61, 990-996.	1.5	16
64	Secondary malignant neoplasms after highâ€dose chemotherapy and autologous stem cell rescue for highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2014, 61, 1350-1356.	1.5	40
65	Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 2014, 61, 627-635.	1.5	71
66	Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database. Journal of Clinical Oncology, 2014, 32, 1228-1235.	1.6	28
67	Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology, 2014, 32, 3169-3176.	1.6	154
68	Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 2014, 61, 1932-1939.	1.5	32
69	Validation of a prognostic multiâ€gene signature in highâ€risk neuroblastoma using the high throughput digital NanoString nCounterâ„¢ system. Molecular Oncology, 2014, 8, 669-678.	4.6	32
70	TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma. Cell Reports, 2014, 7, 1343-1352.	6.4	146
71	Secreted Protein Acidic and Rich in Cysteine. , 2014, , 1-6.		0
72	Secreted Protein Acidic and Rich in Cysteine. , 2014, , 4147-4151.		0

#	Article	IF	Citations
73	Peripheral neuroblastic tumors with genotypeâ€“phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatric Blood and Cancer, 2013, 60, 363-370.	1.5	25
74	Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatric Blood and Cancer, 2013, 60, 985-993.	1.5	285
75	Progressionâ€free survival of two cases of highâ€risk neuroblastoma with refractory/relapsed disease following surgery alone. Pediatric Blood and Cancer, 2013, 60, 512-514.	1.5	0
76	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 999-1008.	10.7	246
77	Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Childrenâ€™s Oncology Group. Journal of Nuclear Medicine, 2013, 54, 541-548.	5.0	169
78	Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. Pediatric Blood and Cancer, 2013, 60, 332-335.	1.5	3
79	Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. Cancer, 2013, 119, 3718-3726.	4.1	67
80	Genetically InFormed Therapiesâ€”A â€œGIFTâ€•for Children with Cancer. Clinical Cancer Research, 2012, 18, 2735-2739.	7.0	7
81	Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival. Journal of the National Cancer Institute, 2012, 105, 302-309.	6.3	30
82	A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants. Annals of Surgery, 2012, 256, 573-580.	4.2	152
83	Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation, and Alters DNA Methylation in Human Neuroblastoma. Cancer Research, 2012, 72, 4714-4723.	0.9	35
84	Using Germline Genomics to Individualize Pediatric Cancer Treatments. Clinical Cancer Research, 2012, 18, 2791-2800.	7.0	25
85	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. European Journal of Cancer, 2012, 48, 1185-1191.	2.8	14
86	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkinâ€™s lymphoma, and neuroblastoma. Targeted Oncology, 2012, 7, 199-210.	3.6	28
87	Opsoclonusâ€myoclonus and antiâ€Hu positive limbic encephalitis in a patient with neuroblastoma. Pediatric Blood and Cancer, 2012, 58, 472-474.	1.5	17
88	Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641. Journal of Clinical Oncology, 2012, 30, 1842-1848.	1.6	174
89	Locoregional MYCNâ€amplified neuroblastoma. Pediatric Blood and Cancer, 2012, 59, 736-738.	1.5	0
90	Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatric Blood and Cancer, 2012, 59, 642-647.	1.5	23

#	Article	IF	Citations
91	New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatric Blood and Cancer, 2012, 58, 1099-1105.	1.5	26
92	Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 4351-4357.	1.6	124
93	Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project. Radiology, 2011, 261, 243-257.	7.3	386
94	Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. European Journal of Cancer, 2011, 47, 561-571.	2.8	94
95	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology, 2011, 29, 3286-3292.	1.6	248
96	The quinoxaline antiâ€tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. Pediatric Blood and Cancer, 2011, 56, 164-167.	1.5	23
97	ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux. Journal of the National Cancer Institute, 2011, 103, 1236-1251.	6.3	113
98	Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2011, 17, 6858-6866.	7.0	88
99	Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age. Journal of Clinical Oncology, 2011, 29, 4358-4364.	1.6	69
100	Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 208-213.	1.6	127
101	Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 76-82.	1.6	109
102	Secreted Protein Acidic and Rich in Cysteine Is a Matrix Scavenger Chaperone. PLoS ONE, 2011, 6, e23880.	2.5	52
103	Advances in the treatment of neuroblastoma. Clinical Advances in Hematology and Oncology, 2011, 9, 865-7.	0.3	0
104	Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 737-743.	2.3	16
105	Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer, 2010, 10, 286.	2.6	22
106	Clinical outcome in children with recurrent neuroblastoma treated with ABTâ€751 and effect of ABTâ€751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. Pediatric Blood and Cancer, 2010, 54, 47-54.	1.5	22
107	Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2010, 28, 3808-3815.	1.6	100
108	Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study. Journal of Clinical Oncology, 2010, 28, 4969-4975.	1.6	220

#	Article	IF	Citations
109	Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Molecular Cancer, 2010, 9, 138.	19.2	44
110	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. New England Journal of Medicine, 2010, 363, 1313-1323.	27.0	253
111	Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. New England Journal of Medicine, 2010, 363, 1324-1334.	27.0	1,460
112	Modulation of matrix remodeling by SPARC in neoplastic progression. Seminars in Cell and Developmental Biology, 2010, 21, 55-65.	5.0	128
113	Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database. Journal of Clinical Oncology, 2009, 27, 365-370.	1.6	111
114	The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. Journal of Clinical Oncology, 2009, 27, 298-303.	1.6	869
115	Progress in Defining and Treating High-Risk Neuroblastoma: Lessons From the Bench and Bedside. Journal of Clinical Oncology, 2009, 27, 1003-1004.	1.6	17
116	Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatric Blood and Cancer, 2009, 53, 563-569.	1.5	79
117	Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors. Modern Pathology, 2009, 22, 950-958.	5.5	44
118	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. Journal of Clinical Oncology, 2009, 27, 289-297.	1.6	1,540
119	Are molecular neuroblastoma classifiers ready for prime time?. Lancet Oncology, The, 2009, 10, 641-642.	10.7	6
120	Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pediatric Blood and Cancer, 2008, 50, 679-680.	1.5	17
121	Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2008, 51, 589-592.	1.5	58
122	Management of Tumor Lysis Syndrome: Need for Evidence-Based Guidelines. Journal of Clinical Oncology, 2008, 26, 5657-5658.	1.6	17
123	A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. Clinical Cancer Research, 2008, 14, 1111-1115.	7.0	45
124	Clinical Significance of MYCN Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2008, 26, 913-918.	1.6	67
125	3 + 3 â‰¥ (Rolling) 6. Journal of Clinical Oncology, 2008, 26, 170-171.	1.6	11
126	Methylation ofCASP8, DCR2, andHIN-1in Neuroblastoma Is Associated with Poor Outcome. Clinical Cancer Research, 2007, 13, 3191-3197.	7.0	98

#	Article	IF	Citations
127	Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma. Clinical Cancer Research, 2007, 13, 3499-3506.	7.0	35
128	Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in Neuroblastoma. Cancer Research, 2007, 67, 1716-1724.	0.9	84
129	Neuroblastoma. Lancet, The, 2007, 369, 2106-2120.	13.7	1,856
130	High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene. Cancer Genetics and Cytogenetics, 2007, 174, 100-110.	1.0	34
131	Excellent local tumor control regardless of extent of surgical resection after treatment on the Chicago Pilot II protocol for neuroblastoma. Journal of Pediatric Surgery, 2006, 41, 271-276.	1.6	16
132	Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: Saving for a rainy day. Pediatric Blood and Cancer, 2006, 46, 719-722.	1.5	19
133	SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. International Journal of Cancer, 2006, 118, 310-316.	5.1	100
134	The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma. Cancer Research, 2006, 66, 2826-2833.	0.9	78
135	Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma. Journal of Clinical Oncology, 2006, 24, 1546-1553.	1.6	155
136	Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study. Clinical Cancer Research, 2006, 12, 5693-5697.	7.0	35
137	A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. Clinical Cancer Research, 2006, 12, 4882-4887.	7.0	45
138	Positive association between congenital anomalies and risk of neuroblastoma. Pediatric Blood and Cancer, 2005, 45, 649-655.	1.5	27
139	Treatment of Neuroblastoma. Pediatric Oncology, 2005, , 123-192.	0.5	2
140	Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Molecular Cancer Therapeutics, 2005, 4, 547-553.	4.1	127
141	Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6466-6473.	1.6	135
142	Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy. Journal of Clinical Oncology, 2005, 23, 8819-8827.	1.6	74
143	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. New England Journal of Medicine, 2005, 353, 2243-2253.	27.0	495
144	The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Letters, 2005, 228, 257-266.	7.2	48

#	Article	IF	Citations
145	Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. Cancer Letters, 2005, 228, 283-299.	7.2	53
146	â€˜Cross-talkâ€™ between Schwannian stroma and neuroblasts promotes neuroblastoma tumor differentiation and inhibits angiogenesis. Cancer Letters, 2005, 228, 125-131.	7.2	26
147	Cross-Talk between Schwann Cells and Neuroblasts Influences the Biology of Neuroblastoma Xenografts. American Journal of Pathology, 2005, 166, 891-900.	3.8	43
148	Protocol for the Examination of Specimens From Patients With Neuroblastoma and Related Neuroblastic Tumors. Archives of Pathology and Laboratory Medicine, 2005, 129, 874-883.	2.5	22
149	Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma. Clinical Cancer Research, 2004, 10, 8493-8500.	7.0	81
150	Scintigraphic Response by 123I-Metaiodobenzylguanidine Scan Correlates With Event-Free Survival in High-Risk Neuroblastoma. Journal of Clinical Oncology, 2004, 22, 3909-3915.	1.6	89
151	Methylation-Associated Silencing of the Heat Shock Protein 47 Gene in Human Neuroblastoma. Cancer Research, 2004, 64, 4531-4538.	0.9	35
152	Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARC. Cancer Research, 2004, 64, 7420-7425.	0.9	47
153	Treatment of Relapsed Wilmsâ€™ Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Childrenâ€™s Memorial Hospital. Journal of Clinical Oncology, 2004, 22, 2885-2890.	1.6	64
154	MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene, 2004, 23, 753-762.	5.9	76
155	MYCN amplification remains prognostically strong 20 years after its â€œclinical debutâ€• European Journal of Cancer, 2004, 40, 2639-2642.	2.8	58
156	The regulation of angiogenesis in neuroblastoma. Cancer Letters, 2003, 197, 47-52.	7.2	36
157	Advances in the Diagnosis and Treatment of Neuroblastoma. Oncologist, 2003, 8, 278-292.	3.7	233
158	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Research, 2003, 63, 6299-310.	0.9	85
159	Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study. Journal of Clinical Oncology, 2002, 20, 2284-2292.	1.6	128
160	HuD, a Neuronal-specific RNA-binding Protein, Increases thein Vivo Stability of MYCN RNA. Journal of Biological Chemistry, 2002, 277, 1967-1973.	3.4	53
161	SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Research, 2002, 62, 7357-63.	0.9	134
162	Detection of MYCN Gene Amplification in Neuroblastoma by Fluorescence In Situ Hybridization: A Pediatric Oncology Group Study. Neoplasia, 2001, 3, 105-109.	5.3	79

#	Article	IF	Citations
163	Treatment and Outcome of 83 Children With Intraspinal Neuroblastoma: The Pediatric Oncology Group Experience. Journal of Clinical Oncology, 2001, 19, 1047-1055.	1.6	100
164	Residential Pesticide Exposure and Neuroblastoma. Epidemiology, 2001, 12, 20-27.	2.7	77
165	Natural killer cell lymphoma. Cancer, 2001, 91, 642-646.	4.1	32
166	Antiangiogenic therapy inhibits human neuroblastoma growth. Medical and Pediatric Oncology, 2001, 36, 190-193.	1.0	16
167	Expression of the putative tumour suppressor gene,p73, in neuroblastoma and other childhood tumours. Medical and Pediatric Oncology, 2001, 36, 48-51.	1.0	3
168	Gastrointestinal relapse of leukemia, mimicking acute graft vs. host disease, following a stem cell transplant. , 2000, 34, 287-289.		7
169	Schwann cell-conditioned medium inhibits angiogenesis in vitro and in vivo. Medical and Pediatric Oncology, 2000, 35, 590-592.	1.0	6
170	Prognostic significance ofEPHB6, EFNB2, andEFNB3 expressions in neuroblastoma. Medical and Pediatric Oncology, 2000, 35, 656-658.	1.0	25
171	MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN. Journal of Clinical Oncology, 2000, 18, 3604-3613.	1.6	100
172	Synergy between 5â€² and 3â€² flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells. Neuroscience Letters, 2000, 292, 147-150.	2.1	7
173	Natural History and Biology of Stage A Neuroblastoma: A Pediatric Oncology Group Study. The American Journal of Pediatric Hematology/oncology, 2000, 22, 197-205.	1.3	87
174	Long-term outcome of patients with intraspinal neuroblastoma. Medical and Pediatric Oncology, 1999, 32, 353-359.	1.0	66
175	Clinical Impact and Prognostic Value of Metaiodobenzylguanidine Imaging in Children With Metastatic Neuroblastoma. Journal of Pediatric Hematology/Oncology, 1999, 21, 13-18.	0.6	54
176	Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. Biology of Blood and Marrow Transplantation, 1998, 4, 38-42.	2.0	15
177	Advances in the diagnosis and treatment of neuroblastoma. Current Opinion in Oncology, 1998, 10, 43-51.	2.4	28
178	Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clinical and Experimental Metastasis, 1997, 15, 130-139.	3.3	36
179	Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: A report from the Pediatric Oncology Group. , 1997, 28, 284-288.		151
180	Neuroblastoma: solving a biologic puzzle. Cancer Treatment and Research, 1997, 92, 125-162.	0.5	1

#	Article	IF	Citations
181	Expression of the Gene for Multidrug-Resistanceâ€“Associated Protein and Outcome in Patients with Neuroblastoma. New England Journal of Medicine, 1996, 334, 231-238.	27.0	295
182	Differential Activity of ELAV-like RNA-binding Proteins in Human Neuroblastoma. Journal of Biological Chemistry, 1996, 271, 33587-33591.	3.4	34
183	Binding of a 40-kDa Protein to the N-myc 3Ê¹-Untranslated Region Correlates with Enhanced N-myc Expression in Human Neuroblastoma. Journal of Biological Chemistry, 1996, 271, 33580-33586.	3.4	34
184	Coâ€amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. Genes Chromosomes and Cancer, 1995, 14, 196-203.	2.8	56
185	A Pilot Study of Isotretinoin in the Treatment of Juvenile Chronic Myelogenous Leukemia. New England Journal of Medicine, 1994, 331, 1680-1684.	27.0	99
186	Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. Journal of Pediatrics, 1994, 125, 712-716.	1.8	117
187	Preferential amplification of the paternal allele of the Nâ€“myc gene in human neuroblastomas. Nature Genetics, 1993, 4, 191-194.	21.4	65
188	Evidence for Molecular Heterogeneity in Human Ganglioneuroblastoma. Pediatric Pathology, 1993, 13, 787-796.	0.5	18
189	Smallest region of overlap in Wilms tumor deletions uniquely implicates an 11p13 zinc finger gene as the disease locus. Genomics, 1991, 10, 293-297.	2.9	54
190	Single copies of the N-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus-myoclonus. Cancer, 1988, 62, 723-726.	4.1	47
191	The spectrum of metabolic bone disease in lymphoblastic leukemia. Cancer, 1987, 59, 346-350.	4.1	43
192	Present Status of Serum Tumor Markers in Diagnosis, Prognosis, and Evaluation of Therapy. Cancer Investigation, 1986, 4, 305-327.	1.3	22